Corline Biomedical AB (CLBIO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared Negative results for the last 7 consecutive quarters

NET PROFIT(HY) At SEK -7.24 MM has Grown at -219.22%
OPERATING CASH FLOW(Y) Lowest at SEK -16.71 MM
ROCE(HY) Lowest at -28.03%

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 452 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.10

Return on Equity

-16.74%

Price to Book

5.61

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Jun 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

90.9%

6 Months

138.25%

1 Year

67.43%

2 Years

26.74%

3 Years

63.68%

4 Years

43.7%

5 Years

-13.91%

Corline Biomedical AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

42.81%

EBIT Growth (5y)

-12.23%

EBIT to Interest (avg)

-5.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.14

Sales to Capital Employed (avg)

0.21

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.00%

ROE (avg)

0.88%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.14

EV to EBIT

-35.97

EV to EBITDA

-36.24

EV to Capital Employed

6.73

EV to Sales

60.62

PEG Ratio

Dividend Yield

ROCE (Latest)

-18.71%

ROE (Latest)

-16.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.76% vs 5.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.45% vs 78.17% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.20",
          "val2": "2.10",
          "chgp": "4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.00",
          "val2": "-3.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-3.10",
          "chgp": "-6.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,366.70%",
          "val2": "-1,484.20%",
          "chgp": "11.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -60.80% vs 6.38% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,188.89% vs -178.26% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.80",
          "val2": "25.00",
          "chgp": "-60.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.50",
          "val2": "-0.40",
          "chgp": "-3,275.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.20",
          "val2": "-1.80",
          "chgp": "-1,188.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,390.10%",
          "val2": "-18.30%",
          "chgp": "-137.18%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

2.20

2.10

4.76%

Operating Profit (PBDIT) excl Other Income

-3.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-3.30

-3.10

-6.45%

Operating Profit Margin (Excl OI)

-1,366.70%

-1,484.20%

11.75%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.76% vs 5.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -6.45% vs 78.17% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

9.80

25.00

-60.80%

Operating Profit (PBDIT) excl Other Income

-13.50

-0.40

-3,275.00%

Interest

0.00

Exceptional Items

-10.00

0.00

Consolidate Net Profit

-23.20

-1.80

-1,188.89%

Operating Profit Margin (Excl OI)

-1,390.10%

-18.30%

-137.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -60.80% vs 6.38% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,188.89% vs -178.26% in Dec 2023

All Annual Results

Company CV

About Corline Biomedical AB

Corline Biomedical AB

Pharmaceuticals & Biotechnology

Corline Biomedical AB is a Sweden-based biotechnology company. It develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

Company Coordinates

Company Details

Lefflersgatan 5 , UPPSALA None : 754 50

Tel: 46 18 713090

http://www.corline.se/

Registrar Details